Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.
Public ClinicalTrials.gov record NCT00043446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.
Study identification
- NCT ID
- NCT00043446
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2002
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 23, 2005
Started 2002
United States locations
- U.S. sites
- 5
- U.S. states
- 3
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scripps Health Center | La Jolla | California | 92037 | — |
| USC Women's and Children's Hospital | Los Angeles | California | 90033 | — |
| University of California San Francisco | San Francisco | California | 94115 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Roswell Park Cancer Center | Buffalo | New York | 14263 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Ovarian Neoplasms trials
Other public records listing Ovarian Neoplasms. Sorted by last update posted; newest first. Not a recommendation.
- NCT07764744: Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants Not yet recruiting
- NCT07038369: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations Active, not recruiting
- NCT06751329: A Study of DM002 in Patients With Advanced Solid Tumors Recruiting
- NCT04641247: A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Recruiting
- NCT06543537: Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer Recruiting
- NCT06051695: A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00043446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2005 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00043446 live on ClinicalTrials.gov.